The cohort was divided into those harboring significant AD co‐pathology, either at autopsy (intermediate/high AD neuropathologic change) or with CSF signature indicating AD co‐pathology (t‐tau/Aβ1‐42 > 0.3) (LBD+AD, N = 19), and those without AD co‐pathology (LBD−AD, N = 53). The gene discussed is MAPT; the disease is Alzheimer disease.